Targeting specific immune cells to treat Type 1 diabetes
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands
This study is exploring a new way to treat Type 1 diabetes by using a special therapy that targets and removes the immune cells that harm the insulin-producing cells in your body, aiming to offer a more effective solution for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11087669 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for Type 1 diabetes (T1D) by using a specialized approach that targets and eliminates the immune cells responsible for damaging insulin-producing beta cells. The method involves a unique CAR T cell system that utilizes chimeric antigen ligands to specifically bind to and destroy autoreactive T cells in T1D patients. By identifying and targeting specific T cell receptors associated with T1D, the research aims to provide a precise and effective therapy for this autoimmune condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 diabetes who have autoreactive T cells contributing to their condition.
Not a fit: Patients with Type 1 diabetes who do not have autoreactive T cells or those with other forms of diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that halts the progression of Type 1 diabetes and preserves insulin production.
How similar studies have performed: Preliminary data and previous studies have shown promise in using similar CAR T cell approaches for targeting autoimmune diseases, indicating potential for success in this novel application.
Where this research is happening
Boston, United States
- Boston University (Charles River Campus) — Boston, United States (Active)
Researchers
- Principal investigator: Wong, Wilson — Boston University (Charles River Campus)
- Study coordinator: Wong, Wilson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.